When other eosinophilic asthma manifestations exist (nasal polyps, aspirin-exacerbated respiratory disease [AERD], atopic dermatitis or if eosinophilia persists after a short term of OCS) (88), anti IL5/IL5Rα or dupilumab would be recommended. Here, IL5RA is linked to Increased total eosinophil count.